Effect of propinox and pinaverium bromide on ex vivo colonic motor patterns and their synergistic effect with hyoscine butyl bromide

Autor/a

Traserra, Sara

Lange, Robert

Alcalá-González, Luis Gerardo

Barber Caselles, Claudia

Landolfi, Stefania

Malagelada, Carolina

Altres autors/es

Institut Català de la Salut

[Traserra S] Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Alcalá-González LG, Barber C] Servei d’Aparell Digestiu, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Landolfi S] Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Malagelada C] Servei d’Aparell Digestiu, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain. [Lange R] Opella, a Sanofi company, Frankfurt am Main, Germany

Vall d'Hebron Barcelona Hospital Campus

Data de publicació

2025-06-13T11:09:11Z

2025-06-13T11:09:11Z

2025-04-22



Resum

Abdominal pain; Colonic motility; Hyoscine butylbromide


Dolor abdominal; Motilitat colònica; Butilbromur d'hioscina


Dolor abdominal; Motilidad colónica; Butilbromuro de hioscina


Background: Antispasmodic agents are used to treat abdominal pain. The mode of action of pinaverium bromide and propinox in the colonic tissue has never been characterized. This study aimed to explore whether HBB can complement the antispasmodic effects of these drugs. Methods: Colon samples were procured from the macroscopically normal regions of 33 patients undergoing colon cancer surgery and subjected to muscle bath experiments. Pinaverium bromide and propinox alone and in combination with HBB were assessed under the following conditions: (1) spontaneous phasic contractions (SPCs) induced by isometric stretch (with 1 µM tetrodotoxin); (2) contractility induced by 10–5 M carbachol; (3) the electrical field stimulation (EFS) of the excitatory pathway (in the presence of 1 mM Nω-nitro-L-arginine and 10 µM MRS2179); and (4) an EFS-induced selective excitation of the inhibitory pathway (under nonadrenergic, noncholinergic pharmacological conditions). An isobolographic study was performed to evaluate the possible interaction between pinaverium bromide, or propinox and HBB. Results: Pinaverium bromide and propinox concentration-dependently reduced SPC (10–5 M: 29%–47% reduction) in both muscle layers. Carbachol-induced contractions were partially reduced by pinaverium bromide (10–5 M: 37%–46% reduction) and propinox (10–5 M: 32%–44% reduction) and almost totally inhibited by the combination with HBB. EFS-induced contractions were slightly decreased by pinaverium bromide (10–5 M; circular muscle: 39% reduction, but no effect on longitudinal muscle) and propinox (10–5 M: circular 48% and longitudinal 37%), and to a greater extent, by the combination with HBB. Both pinaverium bromide (10–5 M: 11%) and propinox (10–5 M: 42%) reduced the EFS-induced off-response but not the on-relaxation. The interaction index measured for the combined activity of HBB with pinaverium bromide or propinox was less than 1 in SPC, carbachol-induced contractions, and EFS-induced contractions. Conclusion: The pharmacological profile obtained in this study was consistent with an L-type calcium channel blocker for both pinaverium bromide and propinox, with an unlikely or a weak antimuscarinic effect for the latter. When combined with the antimuscarinic agent HBB, both pinaverium bromide and propinox showed a synergistic inhibition of contractile responses. This finding could have clinical implications, suggesting a combination treatment approach for greater therapeutic benefits.


The author(s) declare that financial support was received for the research and/or publication of this article. This study was funded by Opella, a Sanofi company.

Tipus de document

Article
Versió publicada

Llengua

Anglès

Matèries i paraules clau

Dolor abdominal - Tractament; Parasimpaticolítics - Ús terapèutic; Bromurs; DISEASES::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Signs and Symptoms, Digestive::Abdominal Pain; Other subheadings::Other subheadings::Other subheadings::/drug therapy; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Peripheral Nervous System Agents::Autonomic Agents::Parasympatholytics; Other subheadings::Other subheadings::/therapeutic use; CHEMICALS AND DRUGS::Organic Chemicals::Amines::Quaternary Ammonium Compounds::Butylscopolammonium Bromide; Other subheadings::Other subheadings::/therapeutic use; ENFERMEDADES::afecciones patológicas, signos y síntomas::signos y síntomas::afecciones patológicas, signos y síntomas::signos y síntomas::signos y síntomas digestivos::dolor abdominal; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::fármacos del sistema nervioso periférico::fármacos del sistema nervioso autónomo::parasimpaticolíticos; Otros calificadores::Otros calificadores::/uso terapéutico; COMPUESTOS QUÍMICOS Y DROGAS::compuestos orgánicos::aminas::compuestos de amonio cuaternario::bromuro de butilescopolamonio; Otros calificadores::Otros calificadores::/uso terapéutico

Publicat per

Frontiers Media

Documents relacionats

Frontiers in Pharmacology;16

https://doi.org/10.3389/fphar.2025.1491123

Drets

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

Aquest element apareix en la col·lecció o col·leccions següent(s)